ImmuneWalk Therapeutics raised $7M in Seed financing to expand operations and R&D efforts.
05/08/25, 9:43 AM
Location
pearl riverMoney raised
$7 million
Industry
therapeutics
biotechnology
health care
Round Type
seed
Investors
Immune Walk Management Team, Institutional Investor
ImmuneWalk Therapeutics, a NYC-based clinical stage company focused on modulating immune and inflammatory disease, raised $7M in Seed funding. Backers included institutional investors and the ImmuneWalk management team. The funds will be used to expand operations and R&D efforts. Their lead candidate, IW-601, is in Phase 1 clinical trial.
Company Info
Location
pearl river, new york, united states
Additional Info
ImmuneWalk Therapeutics is a clinical-stage biotechnology company dedicated to developing new therapies for immune-inflammatory diseases. Central to their program is the discovery of a new adhesion checkpoint that regulates the migration of specific immune cells into inflamed tissues. Their lead candidate, IW-601, is an engineered monoclonal antibody demonstrating disease-modifying activity in preclinical models of several diseases. They are currently conducting the POINTGUARD Phase 1 clinical trial.